Analyst Note
| Debbie S. Wang |We expect Smith & Nephew’s integration of the extremities business from Integra LifeSciences to reinforce its narrow economic moat, but thus far, it adds little to our valuation as these products will account for roughly 2% of consolidated revenue. We interpret this acquisition through several lenses.